Published in Cancer Cell on May 15, 2012
p53 mutations in cancer. Nat Cell Biol (2013) 5.18
Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell (2014) 3.68
A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas. Cancer Cell (2015) 1.61
Contribution of p53 to metastasis. Cancer Discov (2014) 1.28
Small molecule induced reactivation of mutant p53 in cancer cells. Nucleic Acids Res (2013) 1.24
Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53. Nat Commun (2013) 1.21
Mitochondria-mediated apoptosis in mammals. Protein Cell (2014) 1.19
The metabolic demands of cancer cells are coupled to their size and protein synthesis rates. Cancer Metab (2013) 1.18
Common drugs and treatments for cancer and age-related diseases: revitalizing answers to NCI's provocative questions. Oncotarget (2012) 1.11
First-order rate-determining aggregation mechanism of p53 and its implications. Proc Natl Acad Sci U S A (2012) 1.06
Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53. Cancer Res (2015) 1.03
Mutant p53: One, No One, and One Hundred Thousand. Front Oncol (2015) 1.02
Therapeutic targeting of the p53 pathway in cancer stem cells. Expert Opin Ther Targets (2012) 1.01
TP53: an oncogene in disguise. Cell Death Differ (2015) 1.00
The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis. Nucleic Acids Res (2012) 0.98
APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase. Cell Death Dis (2013) 0.97
Degradation of mutant p53H175 protein by Zn(II) through autophagy. Cell Death Dis (2014) 0.94
Global effect of inauhzin on human p53-responsive transcriptome. PLoS One (2012) 0.94
Small molecule restoration of wildtype structure and function of mutant p53 using a novel zinc-metallochaperone based mechanism. Oncotarget (2014) 0.92
Small molecule compounds targeting the p53 pathway: are we finally making progress? Apoptosis (2014) 0.90
Tumor suppressor p53 and its gain-of-function mutants in cancer. Acta Biochim Biophys Sin (Shanghai) (2013) 0.89
Mouse models of sarcomas: critical tools in our understanding of the pathobiology. Clin Sarcoma Res (2012) 0.89
Trans-splicing repair of mutant p53 suppresses the growth of hepatocellular carcinoma cells in vitro and in vivo. Sci Rep (2015) 0.88
Targeting the LKB1 tumor suppressor. Curr Drug Targets (2014) 0.87
Reactivating mutant p53 using small molecules as zinc metallochaperones: awakening a sleeping giant in cancer. Drug Discov Today (2015) 0.86
Antifungal drug discovery: the process and outcomes. Future Microbiol (2014) 0.86
Recent discoveries in the cycling, growing and aging of the p53 field. Aging (Albany NY) (2012) 0.85
Targeting p53-MDM2-MDMX loop for cancer therapy. Subcell Biochem (2014) 0.85
The isolation of an RNA aptamer targeting to p53 protein with single amino acid mutation. Proc Natl Acad Sci U S A (2015) 0.83
p53 reactivation: the link to zinc. Cell Cycle (2012) 0.83
Battle against cancer: an everlasting saga of p53. Int J Mol Sci (2014) 0.83
Targeting Oncogenic Mutant p53 for Cancer Therapy. Front Oncol (2015) 0.83
Synthetic metallochaperone ZMC1 rescues mutant p53 conformation by transporting zinc into cells as an ionophore. Mol Pharmacol (2015) 0.82
Activation of p53 by chemotherapeutic agents enhances reovirus oncolysis. PLoS One (2013) 0.82
Recent progress in genetics of aging, senescence and longevity: focusing on cancer-related genes. Oncotarget (2012) 0.82
Targeting the p53 pathway. Surg Oncol Clin N Am (2013) 0.82
MDP, a database linking drug response data to genomic information, identifies dasatinib and statins as a combinatorial strategy to inhibit YAP/TAZ in cancer cells. Oncotarget (2015) 0.82
Small-Molecule Reactivation of Mutant p53 to Wild-Type-like p53 through the p53-Hsp40 Regulatory Axis. Chem Biol (2015) 0.82
The dichotomy of p53 regulation by noncoding RNAs. J Mol Cell Biol (2014) 0.82
A RUNX2-Mediated Epigenetic Regulation of the Survival of p53 Defective Cancer Cells. PLoS Genet (2016) 0.81
Mechanism of initiation of aggregation of p53 revealed by Φ-value analysis. Proc Natl Acad Sci U S A (2015) 0.81
Functional repair of p53 mutation in colorectal cancer cells using trans-splicing. Oncotarget (2015) 0.80
The role of p53 in cancer drug resistance and targeted chemotherapy. Oncotarget (2016) 0.79
A nanobody modulates the p53 transcriptional program without perturbing its functional architecture. Nucleic Acids Res (2014) 0.79
Novel function of cytoplasmic p53 at the interface between mitochondria and the endoplasmic reticulum. Cell Death Dis (2015) 0.79
Anticancer drugs: Reactivating p53. Nat Rev Drug Discov (2012) 0.79
Reactivation of wild-type and mutant p53 by tryptophanolderived oxazoloisoindolinone SLMP53-1, a novel anticancer small-molecule. Oncotarget (2016) 0.79
Mouse p53-deficient cancer models as platforms for obtaining genomic predictors of human cancer clinical outcomes. PLoS One (2012) 0.79
High metallothionein predicts poor survival in glioblastoma multiforme. BMC Med Genomics (2015) 0.79
Reactivation of mutant p53 by a dietary-related compound phenethyl isothiocyanate inhibits tumor growth. Cell Death Differ (2016) 0.77
Chemical Variations on the p53 Reactivation Theme. Pharmaceuticals (Basel) (2016) 0.77
Full-length p53 tetramer bound to DNA and its quaternary dynamics. Oncogene (2016) 0.76
Mutant p53 regulates ovarian cancer transformed phenotypes through autocrine matrix deposition. JCI Insight (2016) 0.76
Back to the Future: Mutant Hunts Are Still the Way To Go. Genetics (2016) 0.75
Neomorphic mutations create therapeutic challenges in cancer. Oncogene (2016) 0.75
The nucleoside analog clitocine is a potent and efficacious readthrough agent. RNA (2017) 0.75
Inhibition of glucosylceramide synthase eliminates the oncogenic function of p53 R273H mutant in the epithelial-mesenchymal transition and induced pluripotency of colon cancer cells. Oncotarget (2016) 0.75
DNA damage checkpoint adaptation genes are required for division of cells harbouring eroded telomeres. Microb Cell (2015) 0.75
Reactivating p53 and Inducing Tumor Apoptosis (RITA) Enhances the Response of RITA-Sensitive Colorectal Cancer Cells to Chemotherapeutic Agents 5-Fluorouracil and Oxaliplatin. Neoplasia (2017) 0.75
Identification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancer. NPJ Breast Cancer (2017) 0.75
Role of NSC319726 in ovarian cancer based on the bioinformatics analyses. Onco Targets Ther (2015) 0.75
A High-Throughput Cell-Based Screen Identified a 2-[(E)-2-Phenylvinyl]-8-Quinolinol Core Structure That Activates p53. PLoS One (2016) 0.75
Structures of oncogenic, suppressor and rescued p53 core-domain variants: mechanisms of mutant p53 rescue. Acta Crystallogr D Biol Crystallogr (2013) 0.75
Functional p53 is required for rapid restoration of daunorubicin-induced lesions of the spleen. BMC Cancer (2013) 0.75
A sensitive liquid chromatography-mass spectrometry bioanalytical assay for a novel anticancer candidate - ZMC1. Biomed Chromatogr (2015) 0.75
Stathmin is overexpressed and regulated by mutant p53 in oral squamous cell carcinoma. J Exp Clin Cancer Res (2017) 0.75
Molecularly targeted therapies for p53-mutant cancers. Cell Mol Life Sci (2017) 0.75
Genomic and metabolic characterization of a chromophobe renal cell carcinoma cell line model (UOK276). Genes Chromosomes Cancer (2017) 0.75
Reviving the guardian of the genome: Small molecule activators of p53. Pharmacol Ther (2017) 0.75
U1 Adaptors suppress the KRAS-MYC oncogenic axis in human pancreatic cancer xenografts. Mol Cancer Ther (2017) 0.75
Integrated genomic analyses of ovarian carcinoma. Nature (2011) 47.72
Mdm2 promotes the rapid degradation of p53. Nature (1997) 21.26
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature (2007) 16.95
Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell (2005) 14.21
Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science (1994) 13.51
Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat (2007) 12.98
Restoration of p53 function leads to tumour regression in vivo. Nature (2007) 12.62
The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer (2006) 11.49
Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol (2008) 11.05
The antioxidant function of the p53 tumor suppressor. Nat Med (2005) 7.57
Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell (2004) 7.22
A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell (2009) 6.03
Modeling the therapeutic efficacy of p53 restoration in tumors. Cell (2006) 5.95
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med (2002) 5.18
TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol (2010) 4.92
Mutant p53 drives invasion by promoting integrin recycling. Cell (2009) 4.75
Gain of function mutations in p53. Nat Genet (1993) 4.19
Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol Cancer Ther (2006) 4.09
Pharmacological rescue of mutant p53 conformation and function. Science (1999) 3.91
Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res (2000) 3.30
The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev (2008) 3.17
Structure-function-rescue: the diverse nature of common p53 cancer mutants. Oncogene (2007) 2.96
p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene (1997) 2.31
Redox modulation of p53 conformation and sequence-specific DNA binding in vitro. Cancer Res (1993) 2.18
Dipyridyl thiosemicarbazone chelators with potent and selective antitumor activity form iron complexes with redox activity. J Med Chem (2006) 2.04
High metastatic potential in mice inheriting a targeted p53 missense mutation. Proc Natl Acad Sci U S A (2000) 1.73
Hot-spot mutants of p53 core domain evince characteristic local structural changes. Proc Natl Acad Sci U S A (1999) 1.73
Structures of p53 cancer mutants and mechanism of rescue by second-site suppressor mutations. J Biol Chem (2005) 1.67
Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide reductase inhibitors. J Med Chem (2009) 1.43
Structure, function, and aggregation of the zinc-free form of the p53 DNA binding domain. Biochemistry (2003) 1.41
Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs. J Biol Chem (2005) 1.37
A structural role for metal ions in the "wild-type" conformation of the tumor suppressor protein p53. Cancer Res (1993) 1.33
Optimal drug combinations and minimal hitting sets. BMC Syst Biol (2009) 1.18
Future of toxicology--iron chelators and differing modes of action and toxicity: the changing face of iron chelation therapy. Chem Res Toxicol (2007) 1.10
2-Acetylpyridine thiosemicarbazones are potent iron chelators and antiproliferative agents: redox activity, iron complexation and characterization of their antitumor activity. J Med Chem (2009) 0.95
Restoration of wild-type conformation and activity of a temperature-sensitive mutant of p53 (p53(V272M)) by the cytoprotective aminothiol WR1065 in the esophageal cancer cell line TE-1. Mol Carcinog (2002) 0.95
Zn(2+)-dependent misfolding of the p53 DNA binding domain. Biochemistry (2007) 0.93
Stochastic gene expression in a single cell. Science (2002) 34.54
Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. Proc Natl Acad Sci U S A (2003) 15.59
High-quality binary protein interaction map of the yeast interactome network. Science (2008) 10.65
The p53 pathway: positive and negative feedback loops. Oncogene (2005) 9.75
Dynamics of the p53-Mdm2 feedback loop in individual cells. Nat Genet (2004) 8.30
A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell (2004) 8.18
Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer (2006) 7.53
The coordinate regulation of the p53 and mTOR pathways in cells. Proc Natl Acad Sci U S A (2005) 7.38
An empirical framework for binary interactome mapping. Nat Methods (2008) 6.59
p53 regulates maternal reproduction through LIF. Nature (2007) 4.12
Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell (2012) 4.09
The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov (2008) 4.03
The regulation of AMPK beta1, TSC2, and PTEN expression by p53: stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways. Cancer Res (2007) 3.55
Epstein-Barr virus and virus human protein interaction maps. Proc Natl Acad Sci U S A (2007) 3.50
MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res (2006) 3.26
The regulation of exosome secretion: a novel function of the p53 protein. Cancer Res (2006) 3.22
MDM2 is a central node in the p53 pathway: 12 years and counting. Curr Cancer Drug Targets (2005) 3.04
Suppression of immediate-early viral gene expression by herpesvirus-coded microRNAs: implications for latency. Proc Natl Acad Sci U S A (2008) 2.90
Identifying mRNA targets of microRNA dysregulated in cancer: with application to clear cell Renal Cell Carcinoma. BMC Syst Biol (2010) 2.49
High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates. Cancer Res (2007) 2.48
Molecular classification of prostate cancer using curated expression signatures. Proc Natl Acad Sci U S A (2011) 2.46
Declining p53 function in the aging process: a possible mechanism for the increased tumor incidence in older populations. Proc Natl Acad Sci U S A (2007) 2.36
The regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 protein. Trends Cell Biol (2010) 2.33
A plausible model for the digital response of p53 to DNA damage. Proc Natl Acad Sci U S A (2005) 2.32
Unexpected inheritance: multiple integrations of ancient bornavirus and ebolavirus/marburgvirus sequences in vertebrate genomes. PLoS Pathog (2010) 2.32
Comparison of avian and human influenza A viruses reveals a mutational bias on the viral genomes. J Virol (2006) 2.06
Highly conserved regions of influenza a virus polymerase gene segments are critical for efficient viral RNA packaging. J Virol (2007) 2.05
Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer. Proc Natl Acad Sci U S A (2012) 1.97
Patterns of evolution and host gene mimicry in influenza and other RNA viruses. PLoS Pathog (2008) 1.96
Negative regulation of tumor suppressor p53 by microRNA miR-504. Mol Cell (2010) 1.92
Tissue-specific codon usage and the expression of human genes. Proc Natl Acad Sci U S A (2004) 1.91
The origins and evolution of the p53 family of genes. Cold Spring Harb Perspect Biol (2009) 1.90
Parkin, a p53 target gene, mediates the role of p53 in glucose metabolism and the Warburg effect. Proc Natl Acad Sci U S A (2011) 1.87
ADAMTS1/METH1 inhibits endothelial cell proliferation by direct binding and sequestration of VEGF165. J Biol Chem (2003) 1.84
WISP-1 attenuates p53-mediated apoptosis in response to DNA damage through activation of the Akt kinase. Genes Dev (2002) 1.80
Single-nucleotide polymorphisms in the p53 pathway regulate fertility in humans. Proc Natl Acad Sci U S A (2009) 1.79
Inactivation of p53 in breast cancers correlates with stem cell transcriptional signatures. Proc Natl Acad Sci U S A (2010) 1.78
p53 and NF-κB: different strategies for responding to stress lead to a functional antagonism. FASEB J (2010) 1.77
The presence of p53 mutations in human osteosarcomas correlates with high levels of genomic instability. Proc Natl Acad Sci U S A (2003) 1.69
A single nucleotide polymorphism in the MDM2 gene disrupts the oscillation of p53 and MDM2 levels in cells. Cancer Res (2007) 1.67
The tumor suppressor p53: cancer and aging. Cell Cycle (2008) 1.66
Epigenetic and genetic loss of Hic1 function accentuates the role of p53 in tumorigenesis. Cancer Cell (2004) 1.65
p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas. Genes Dev (2002) 1.57
Altered tumor formation and evolutionary selection of genetic variants in the human MDM4 oncogene. Proc Natl Acad Sci U S A (2009) 1.54
A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development. Cancer Cell (2010) 1.49
A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells. J Biol Chem (2005) 1.47
Topology based data analysis identifies a subgroup of breast cancers with a unique mutational profile and excellent survival. Proc Natl Acad Sci U S A (2011) 1.40
The regulation of the endosomal compartment by p53 the tumor suppressor gene. FEBS J (2009) 1.39
Sequences from ancestral single-stranded DNA viruses in vertebrate genomes: the parvoviridae and circoviridae are more than 40 to 50 million years old. J Virol (2010) 1.38
Gene Amplifications in Well-Differentiated Pancreatic Neuroendocrine Tumors Inactivate the p53 Pathway. Genes Cancer (2010) 1.38
LGR5-positive colon cancer stem cells interconvert with drug-resistant LGR5-negative cells and are capable of tumor reconstitution. Stem Cells (2012) 1.36
MDM2 SNP309 accelerates colorectal tumour formation in women. J Med Genet (2006) 1.35
Overexpression of WISP-1 down-regulated motility and invasion of lung cancer cells through inhibition of Rac activation. J Biol Chem (2003) 1.29
Haplotype structure and selection of the MDM2 oncogene in humans. Proc Natl Acad Sci U S A (2007) 1.28
Sequence analysis of p53 response-elements suggests multiple binding modes of the p53 tetramer to DNA targets. Nucleic Acids Res (2007) 1.22
Non-random reassortment in human influenza A viruses. Influenza Other Respir Viruses (2008) 1.20
p53: a new player in reproduction. Cell Cycle (2008) 1.20
Anomalies in the influenza virus genome database: new biology or laboratory errors? J Virol (2008) 1.19
The metabolic demands of cancer cells are coupled to their size and protein synthesis rates. Cancer Metab (2013) 1.18
Detection of functional single-nucleotide polymorphisms that affect apoptosis. Proc Natl Acad Sci U S A (2005) 1.18
Multiple roles of p53-related pathways in somatic cell reprogramming and stem cell differentiation. Cancer Res (2012) 1.17
A relative-entropy algorithm for genomic fingerprinting captures host-phage similarities. J Bacteriol (2005) 1.14
Autophagy regulator BECN1 suppresses mammary tumorigenesis driven by WNT1 activation and following parity. Autophagy (2014) 1.14
Chemosensitivity profiles identify polymorphisms in the p53 network genes 14-3-3tau and CD44 that affect sarcoma incidence and survival. Cancer Res (2009) 1.13
Association of nuclear localization of a long interspersed nuclear element-1 protein in breast tumors with poor prognostic outcomes. Genes Cancer (2010) 1.12
p63 regulates glutaminase 2 expression. Cell Cycle (2013) 1.12
Patterns of oligonucleotide sequences in viral and host cell RNA identify mediators of the host innate immune system. PLoS One (2009) 1.12
Amplified loci on chromosomes 8 and 17 predict early relapse in ER-positive breast cancers. PLoS One (2012) 1.10
Regulation of female reproduction by p53 and its family members. FASEB J (2011) 1.08
Chronic restraint stress attenuates p53 function and promotes tumorigenesis. Proc Natl Acad Sci U S A (2012) 1.08
One billion years of p53/p63/p73 evolution. Proc Natl Acad Sci U S A (2009) 1.08
The Regulation of Multiple p53 Stress Responses is Mediated through MDM2. Genes Cancer (2012) 1.06
Stem cell biology meets p53. Nat Biotechnol (2009) 1.04
A polymorphic variant in human MDM4 associates with accelerated age of onset of estrogen receptor negative breast cancer. Carcinogenesis (2009) 1.03
Spreading dynamics following bursty human activity patterns. Phys Rev E Stat Nonlin Soft Matter Phys (2011) 1.03
CIAP1 and the serine protease HTRA2 are involved in a novel p53-dependent apoptosis pathway in mammals. Genes Dev (2003) 1.02
Novel gain of function activity of p53 mutants: activation of the dUTPase gene expression leading to resistance to 5-fluorouracil. Oncogene (2002) 1.01
Activation of NF-kappaB and inhibition of p53-mediated apoptosis by API2/mucosa-associated lymphoid tissue 1 fusions promote oncogenesis. Proc Natl Acad Sci U S A (2004) 0.99
Differential levels of transcription of p53-regulated genes by the arginine/proline polymorphism: p53 with arginine at codon 72 favors apoptosis. FASEB J (2009) 0.99
Germline mutations and polymorphisms in the origins of cancers in women. J Oncol (2010) 0.96
Lactase persistence and lipid pathway selection in the Maasai. PLoS One (2012) 0.95
Attenuation of the retinoblastoma pathway in pancreatic neuroendocrine tumors due to increased cdk4/cdk6. Clin Cancer Res (2012) 0.94
Comparison of the protein-protein interfaces in the p53-DNA crystal structures: towards elucidation of the biological interface. Proc Natl Acad Sci U S A (2005) 0.93
Recent natural selection identifies a genetic variant in a regulatory subunit of protein phosphatase 2A that associates with altered cancer risk and survival. Clin Cancer Res (2009) 0.92
Small molecule compounds targeting the p53 pathway: are we finally making progress? Apoptosis (2014) 0.90
The regulation of human reproduction by p53 and its pathway. Cell Cycle (2009) 0.90
Viral reassortment as an information exchange between viral segments. Proc Natl Acad Sci U S A (2012) 0.90
A robust meta-classification strategy for cancer detection from MS data. Proteomics (2006) 0.89
Intraoperative fluid administration is associated with perioperative outcomes in pancreaticoduodenectomy: a single center retrospective analysis. J Surg Oncol (2013) 0.88
Comparison of the human and worm p53 structures suggests a way for enhancing stability. Biochemistry (2006) 0.88
Probing potential binding modes of the p53 tetramer to DNA based on the symmetries encoded in p53 response elements. Nucleic Acids Res (2007) 0.88
Polymorphic variants in TSC1 and TSC2 and their association with breast cancer phenotypes. Breast Cancer Res Treat (2010) 0.87
Carbon catabolite repression correlates with the maintenance of near invariant molecular crowding in proliferating E. coli cells. BMC Syst Biol (2013) 0.87
In the quest for stable rescuing mutants of p53: computational mutagenesis of flexible loop L1. Biochemistry (2005) 0.86
Robust diagnosis of non-Hodgkin lymphoma phenotypes validated on gene expression data from different laboratories. Genome Inform (2005) 0.84